Wiskott-Aldrich syndrome gene therapy - Genethon

Drug Profile

Wiskott-Aldrich syndrome gene therapy - Genethon

Alternative Names: WAS gene therapy - Genethon

Latest Information Update: 15 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genethon
  • Developer Childrens Hospital Boston; Genethon
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Wiskott-Aldrich syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Wiskott-Aldrich syndrome

Most Recent Events

  • 21 Sep 2015 Phase I/II development is ongoing in USA, France and United Kingdom
  • 21 Apr 2015 Interim efficacy data from a phase I/II trial in Wiskott-Aldrich syndrome released by Genethon
  • 01 Sep 2014 Genethon initiates a long term safety follow up trial for Wiskott-Aldrich Syndrome in France and United Kingdom (NCT02333760)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top